Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
135M
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
98.4M
-
Shares change
-
+4.75M
-
Total reported value, excl. options
-
$781M
-
Value change
-
+$30.6M
-
Put/Call ratio
-
0.8
-
Number of buys
-
56
-
Number of sells
-
-52
-
Price
-
$7.94
Significant Holders of Tango Therapeutics, Inc. - Common Stock (TNGX) as of Q1 2024
139 filings reported holding TNGX - Tango Therapeutics, Inc. - Common Stock as of Q1 2024.
Tango Therapeutics, Inc. - Common Stock (TNGX) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.4M shares
of 135M outstanding shares and own 73.08% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (19.2M shares), EcoR1 Capital, LLC (13.3M shares), FMR LLC (9.49M shares), Boxer Capital, LLC (8.2M shares), Nextech Invest Ltd. (5.53M shares), Southpoint Capital Advisors LP (5.28M shares), T. Rowe Price Investment Management, Inc. (4.32M shares), BlackRock Inc. (3.86M shares), VANGUARD GROUP INC (3.08M shares), and Bain Capital Life Sciences Investors, LLC (2.89M shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.